免疫检查点抑制剂相关肺炎的早期识别与糖皮质激素治疗策略
摘要
肺炎为代表的免疫相关不良事件（immune-related adverse events，irAEs）。其中，免疫检查点抑制剂相关肺炎（checkpoint
inhibitor-related pneumonitis，CIP）具有较高的潜在致死风险，已成为临床管理的难点与重点。CIP起病隐匿，临床症状
缺乏特异性，易被误诊为感染或肿瘤进展，常导致治疗延误、预后不良。规范的早期识别、分级评估以及糖皮质激素治
疗，对于改善患者结局至关重要。本文系统梳理CIP的发病机制、临床表现、辅助检查、诊断流程及激素治疗策略，旨
在为临床实践提供科学、可操作的诊疗依据。
全文:
PDF参考
[1]Ramos-Casals M，Brahmer JR，Callahan MK，et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers，
2020，6（1）：38.
[2]Berner F，Bomze D，Diem S，et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in
non-small cell lung cancer[J]. JAMA Oncol，2019，5（7）：1043–1047.
[3]Khunger M，Rakshit S，Pasupuleti V，et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand
1 inhibitors in non-small cell lung cancer：A systematic review and meta-analysis of trials[J]. Chest，2017，152（2）：271–281.
[4]Nishino M，Giobbie-Hurder A，Hatabu H，et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with
advanced cancer：A systematic review and meta-analysis[J]. JAMA Oncol，2016，2（12）：1607–1616.
[5]Atchley WT，Alvarez C，Saxena-Beem S，et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer：Real-world
incidence，risk factors，and management practices across six health care centers in North Carolina[J]. Chest，2021，160（2）：731–
742.
[6]Naidoo J，Wang X，Woo KM，et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand-1
therapy[J]. J Clin Oncol，2017，35（7）：709–717.
[7]Okiyama N，Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors[J]. Allergol Int，
2022，71（2）：169–178.
[8]Yanagihara T，Tanaka K，Ota K，et al. Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic
kidney cancer of the chest wall during nivolumab treatment[J]. Ann Oncol，2017，28（8）：2038–2039.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。